IDEXX Laboratories, Inc. $IDXX Shares Acquired by Portland Global Advisors LLC

Portland Global Advisors LLC grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 323.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 8,147 shares of the company’s stock after acquiring an additional 6,224 shares during the period. Portland Global Advisors LLC’s holdings in IDEXX Laboratories were worth $5,512,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Railway Pension Investments Ltd raised its holdings in shares of IDEXX Laboratories by 10.0% in the 4th quarter. Railway Pension Investments Ltd now owns 326,080 shares of the company’s stock valued at $220,603,000 after purchasing an additional 29,550 shares in the last quarter. MUFG Securities EMEA plc grew its position in shares of IDEXX Laboratories by 113.8% in the 4th quarter. MUFG Securities EMEA plc now owns 3,274 shares of the company’s stock valued at $2,215,000 after buying an additional 1,743 shares during the last quarter. Sfmg LLC grew its position in shares of IDEXX Laboratories by 68.0% in the 4th quarter. Sfmg LLC now owns 1,045 shares of the company’s stock valued at $707,000 after buying an additional 423 shares during the last quarter. Wormser Freres Gestion grew its position in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 47 shares during the last quarter. Finally, Walter Public Investments Inc. purchased a new position in shares of IDEXX Laboratories in the 4th quarter valued at $6,740,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Piper Sandler dropped their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Barclays dropped their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Trading Down 0.8%

Shares of IDEXX Laboratories stock opened at $563.53 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $504.56 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The company has a market capitalization of $44.45 billion, a P/E ratio of 41.50, a PEG ratio of 3.27 and a beta of 1.58. The company’s fifty day moving average is $564.58 and its two-hundred day moving average is $637.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the firm posted $2.91 EPS. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,758 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the transaction, the executive vice president directly owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.79% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.